Brief 2019 on Conjugate Vaccine Market Growth Exhibit at 10.5% CAGR, By Indication, Type, Global Industry Share, Size, Advancements and Trend Forecast 2023

“Conjugate Vaccine Market”
Emerging R&D for new product development and growing incidences of infectious diseases favour the growth of conjugate vaccines market over the forecast up to 2023

North America, Europe to Dominate Conjugate Vaccine Market due to Strong Presence of Healthcare Industry

In March 2019, Pfizer initiated three phase III trials on its new 20-valent pneumococcal conjugate vaccine.

Conjugate Vaccines Market

Conjugate vaccines are vaccines containing two antigens, one strong and one weak. The stronger antigen is generally made from proteins and is attached to a weaker polysaccharide antigen to form conjugate vaccines. Conjugate vaccines are used to counter diseases whose associated pathogens do not elicit a significant response from the human immune system on their own.

The global conjugate vaccines market is expected to exhibit a robust 10.5% CAGR over the forecast period, according to MRFR.

As a result, a stronger antigen is attached to the weaker pathogen to make it more prominent and to elicit a stronger response from the immune system. The first conjugate vaccine was developed in response to the outbreak of meningitis, which still remains among the top targeted diseases in the conjugate vaccines market.

The growing support for further advancement in vaccine research and development is also likely to be a major driver for the global conjugate vaccines market over the forecast period. Considerable growth in vaccine development efforts from major market players is likely to be a major driver for the conjugate vaccines market over the forecast period.

Get Free Sample Research copy at https://www.marketresearchfuture.com/sample_request/4387

Regional Analysis:

The global conjugate vaccines market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominates the global conjugate vaccines market due to the growing demand for wide-scale disease eradication through vaccines and the growing vaccine research environment in advanced countries such as the U.S. and Canada. The growing government support to vaccination and vaccine development in this region, along with the presence of a strong and advanced biotechnology sector in the region, is also likely to be a major driver for the conjugate vaccines market over the forecast period.

Europe follows the Americas region in terms of its share in the global conjugate vaccines market and is likely to remain in a leading position through the forecast period due to the growing awareness about vaccines in Europe and the growing demand for developing cost-efficient, effective formulations of vaccines. The strong presence of the medical biotechnology sector in the region is also likely to be a major driver for the conjugate vaccines market in Europe.

Asia Pacific follows Europe in the global conjugate vaccines market and is likely to hold a reasonable share in the global market over the forecast period due to the growing awareness about the importance of vaccination in countries such as China and India. The growing population of this region is likely to drive the conjugate vaccines market in Asia Pacific over the forecast period.

Competitive Analysis:

Leading players in the global conjugate vaccine market include GSK plc, Fablife, Sanofi Pasteur SA, Sinovac Biotech Ltd., GreenSignal Bio Pharma Limited, Bavarian Nordic, Taj Pharmaceuticals Limited, IDT Biologics, Pfizer, SutroVax Inc., and Merck & Co. Inc.

Brows complete Premium Research report at https://www.marketresearchfuture.com/reports/conjugate-vaccine-market-4387

Segmentation:

The global conjugate vaccine market is segmented on the basis of type, indication, end user, and region.

On the basis of type, the global conjugate vaccine market is segmented into haemophilus B, monovalent, multivalent, and others.

On the basis of indication, the conjugate vaccines market is segmented into influenza, pneumococcal, meningococcal, and others. Influenza dominates the global conjugate vaccines market with a 35% share, however, pneumococcal and meningococcal vaccines are also likely to take up a considerable share of the global conjugate vaccines market over the forecast period.

Global Conjugate Vaccines Market, by Indication (%)

 Conjugate Vaccine Market Research Report - Global Forecast till 2023 -Report image 00

On the basis of end users, the market is segmented into pediatrics and adults.

TABLE OF CONTENTS

1 Report Prologue

2 Market Introduction

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Supply Chain Analysis

6 Global Conjugates Vaccines Market, By Type

6.1 Haemophilus B

6.2 Monovalent

6.3 Multivalent

6.4 Others

7 Global Conjugates Vaccines Market, By Indication

7.1 Influenza

7.2 Pneumococcal

…continued.

Ask for discount at https://www.marketresearchfuture.com/check-discount/4387

About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/press-release/conjugate-vaccines-industry